Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?

被引:65
作者
Brothman, AR
Swanson, G
Maxwell, TM
Cui, J
Murphy, KJ
Herrick, J
Speights, VO
Isaac, J
Rohr, LR
机构
[1] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84132 USA
[2] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA
[3] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA
[4] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT USA
[5] Univ Utah, Sch Med, Dept Hlth, Salt Lake City, UT USA
[6] US Oncol, Spokane, WA USA
[7] Scott & White Hosp, Temple, TX USA
关键词
D O I
10.1016/j.cancergencyto.2004.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was designed to determine if cytological detection of 5-methylcytosine (5MC) was feasible on prostate tumor sections and to determine if levels of 5MC differed in malignant compared to normal prostate tissue. We further sought to see if 5MC levels correlated with any clinical outcome data. Thirty prostate tumor sections were obtained from patients who underwent radical prostatectomies from 1988 to 1995; these represented a mix of low to high grade tumors. Clinical data were maintained for each of these patients with a minimum of 7 years of follow up. Sections were stained with a commercially available antibody to 5MC and immunocytochemistry levels were subsequently quantified using a computer-assisted true-color imaging system. Tumor and benign regions of the same archived sections were compared, in addition to a series of 12 normal prostate samples. Prostate cancer cells exhibited a pronounced global decrease in methylation compared with benign and normal tissue. This was observed in 29 of 30 patients (96.7%) studied and densitometric scanning of methylation staining indicated that this value was quantifiable. Overall, higher methylation values were detected in men who had positive surgical margins and recurrent disease. These data suggest that loss of methylation is a feature of prostate cancer, and partial gain of methylation (presumably at promoters of specific genes) is associated with clinical outcome and is measurable using whole-cell assays. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 21 条
[1]   DNA hypermethylation in tumorigenesis - epigenetics joins genetics [J].
Baylin, SB ;
Herman, JG .
TRENDS IN GENETICS, 2000, 16 (04) :168-174
[2]  
BEDFORD MT, 1987, CANCER RES, V47, P5274
[3]   Cytogenetics and molecular genetics of cancer of the prostate [J].
Brothman, AR .
AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 115 (03) :150-156
[4]  
Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO
[5]  
2-#
[6]   Pathological and molecular aspects of prostate cancer [J].
DeMarzo, AM ;
Nelson, WG ;
Isaacs, WB ;
Epstein, JI .
LANCET, 2003, 361 (9361) :955-964
[7]   DNA methylation in cancer: too much, but also too little [J].
Ehrlich, M .
ONCOGENE, 2002, 21 (35) :5400-5413
[8]  
Esteller M, 1999, CANCER RES, V59, P67
[9]  
Esteller M, 2001, CANCER RES, V61, P3225
[10]   THE 5-METHYLCYTOSINE CONTENT OF DNA FROM HUMAN-TUMORS [J].
GAMASOSA, MA ;
SLAGEL, VA ;
TREWYN, RW ;
OXENHANDLER, R ;
KUO, KC ;
GEHRKE, CW ;
EHRLICH, M .
NUCLEIC ACIDS RESEARCH, 1983, 11 (19) :6883-6894